Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Study: TripleHormone Receptor Agonist Retatrutide for Obesity (Phase 2 Trial, NEJM) Drug: Retatrutide a triple agonist (GLP-1, GIP, and glucagon receptors) Key Findings: Up to 28.7% mean weight loss at higher doses Marked improvements in insulin sensitivity and cardiometabolic risk factors Weight loss approaching outcomes seen with bariatric surgery, without surgery What makes Retatrutide unique is its triple-hormone mechanism, simultaneously targeting appetite regulation, energy expenditure, and glucose metabolism
Another branded form, Wegovy, is approved specifically for weight loss
Understanding Semaglutide Semaglutide belongs to a class of medications known as GLP-1 receptor agonists
The important part here is that it synergizes with semaglutide for weight loss, morning energy, and alertness
In 2025, the GLP-1 receptor agonist market was valued at $66.4 billion and is projected to grow to $82 billion in 2026
Weight loss follows later
US$ 28.88
US$ 26.91
US$ 29.15
US$ 21.64
US$ 26.79
US$ 29.84
US$ 20.46
US$ 25.06
US$ 23.40
US$ 22.38
US$ 25.43
US$ 24.74
US$ 22.68
US$ 24.13
